Add to ORKGThe importance of neovascularization for primary and metastatic tumor growth fostered numerous clinical trials of angiogenesis inhibitors either alone or in combination with conventional antineoplastic therapies. One challenge with the use of molecularly
Despite the numerous available drugs, the most appropriate treatments for patients affected by commo...
peer reviewedRenal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, i...
Contains fulltext : 69826.pdf (publisher's version ) (Open Access)The treatment of...
The importance of neovascularization for primary and metastatic tumor growth fostered numerous clini...
International audienceSince 2004, the treatment of metastatic renal cell carcinoma is in deep mutati...
Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC...
There are now a variety of therapies approved for the treatment of metastatic renal cell carcinoma (...
International audienceThe development of targeted molecules in renal carcinogenesis changed the ther...
National audienceUntil 2006, immunotherapy (interferon-alpha or interleukin 2) was the standard medi...
Therapeutic options in advanced renal-cell cancer have expanded through better understanding of mole...
Neoangiogenesis associated with tumours is formation of new blood vessels from pre-existing quiescen...
For several decades, metastatic renal cell carcinoma (mRCC) was considered resistant to therapy and ...
International audienceThe anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treati...
Clear cell renal cell cancer (ccRCC) prominently expresses vascular endothelial growth factor-A (VEG...
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-...
Despite the numerous available drugs, the most appropriate treatments for patients affected by commo...
peer reviewedRenal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, i...
Contains fulltext : 69826.pdf (publisher's version ) (Open Access)The treatment of...
The importance of neovascularization for primary and metastatic tumor growth fostered numerous clini...
International audienceSince 2004, the treatment of metastatic renal cell carcinoma is in deep mutati...
Antiangiogenic therapy has shown promise in the treatment of patients with renal cell carcinoma (RCC...
There are now a variety of therapies approved for the treatment of metastatic renal cell carcinoma (...
International audienceThe development of targeted molecules in renal carcinogenesis changed the ther...
National audienceUntil 2006, immunotherapy (interferon-alpha or interleukin 2) was the standard medi...
Therapeutic options in advanced renal-cell cancer have expanded through better understanding of mole...
Neoangiogenesis associated with tumours is formation of new blood vessels from pre-existing quiescen...
For several decades, metastatic renal cell carcinoma (mRCC) was considered resistant to therapy and ...
International audienceThe anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treati...
Clear cell renal cell cancer (ccRCC) prominently expresses vascular endothelial growth factor-A (VEG...
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-...
Despite the numerous available drugs, the most appropriate treatments for patients affected by commo...
peer reviewedRenal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, i...
Contains fulltext : 69826.pdf (publisher's version ) (Open Access)The treatment of...